Correction: Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (Cancer Cell (2016) 30(3) (500) (S1535610816300381) (10.1016/j.ccell.2016.02.004));Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

Cancer Cell

Volumn 29, Issue 3, 2016, Pages 285-296

  Tang, Haidong ^a,b   Wang, Yang ^a,b   Chlewicki, Lukasz K ^a   Zhang, Yuan ^a   Guo, Jingya ^c   Liang, Wei ^c   Wang, Jieyi ^d   Wang, Xiaoxiao ^e   Fu, Yang Xin ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c INSTITUTE OF BIOPHYSICS   (China)

^d ABBVIE INC   (United States)

^e Alphamab Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; HYBRID PROTEIN; LYMPHOTOXIN BETA RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; IMMUNITY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LYMPHOTOXIN BETA RECEPTOR; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962921798     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.08.011     Document Type: Erratum

References (58)

1. Ai M., Curran M.A. Immune checkpoint combinations from mouse to man. Cancer Immunol. Immunother. 2015, 64:1-8.
2. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004, 64:1140-1145.
3. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 1997, 15:553-557.
4. Boussemart L., Routier E., Mateus C., Opletalova K., Sebille G., Kamsu-Kom N., Thomas M., Vagner S., Favre M., Tomasic G. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann. Oncol. 2013, 24:1691-1697.
5. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.-J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
6. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat. Immunol. 2008, 9:970-980.
7. Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., Fong L. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 2014, 6:238ra270.
8. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellström I., Hellström K. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 1994, 179:523-532.
9. Crespo J., Sun H., Welling T.H., Tian Z., Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:214-221.
10. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
11. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs. Science 1999, 286:2098-2102.
12. da Silva R.B., Laird M.E., Yatim N., Fiette L., Ingersoll M.A., Albert M.L. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol. 2015, 16:850-858.
13. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., Li Z.-W., Karin M., Ware C.F., Green D.R. The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 2002, 17:525-535.
14. Del Rio M., Lucas C., Buhler L., Rayat G., Rodriguez-Barbosa J. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. 2010, 87:223-235.
15. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 2006, 80:1183-1196.
16. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
17. Fu Y.-X., Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 1999, 17:399-433.
18. Gajewski T.F., Schreiber H., Fu Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14:1014-1022.
19. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
20. Hammers H.J., Plimack E.R., Infante J.R., Ernstoff M.S., Rini B.I., McDermott D.F., Razak A.R., Pal S.K., Voss M.H., Sharma P. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 2014, 32:5s. (suppl; abstr 4504).
21. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
22. Hwang W.-T., Adams S.F., Tahirovic E., Hagemann I.S., Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 2012, 124:192-198.
23. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99:12293-12297.
24. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
25. Lee Y., Chin R.K., Christiansen P., Sun Y., Tumanov A.V., Wang J., Chervonsky A.V., Fu Y.-X. Recruitment and activation of naive T cells in the islets by lymphotoxin β receptor-dependent tertiary lymphoid structure. Immunity 2006, 25:499-509.
26. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., Beckett M., Sharma R., Chin R., Tu T. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
27. Lo J.C., Chin R.K., Lee Y., Kang H.-S., Wang Y., Weinstock J.V., Banks T., Ware C.F., Franzoso G., Fu Y.-X. Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J. Clin. Invest. 2003, 112:1495.
28. Lukashev M., LePage D., Wilson C., Bailly V., Garber E., Lukashin A., Ngam-ek A., Zeng W., Allaire N., Perrin S. Targeting the lymphotoxin-β receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006, 66:9617-9624.
29. Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., Ellis I.O., Green A.R. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011, 29:1949-1955.
30. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellström K.E., Mittler R.S., Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997, 3:682-685.
31. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
32. Peng D., Kryczek I., Nagarsheth N., Zhao L., Wei S., Wang W., Sun Y., Zhao E., Vatan L., Szeliga W. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015, 527:249-253.
33. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol. Pharm. 2010, 8:12-28.
34. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
35. Ruddle N.H. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol. Res. 1999, 19:119-125.
36. Shin D.S., Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr. Opin. Immunol. 2015, 33:23-35.
37. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 (+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014, 2:3.
38. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic [bgr]-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
39. Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 2013, 19:1021-1034.
40. Tähtinen S., Grönberg-Vähä-Koskela S., Lumen D., Merisalo-Soikkeli M., Siurala M., Airaksinen A.J., Vähä-Koskela M., Hemminki A. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol. Res. 2015, 3:915-925.
41. Thompson E.D., Enriquez H.L., Fu Y.-X., Engelhard V.H. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 2010, 207:1791-1804.
42. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
43. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
44. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
45. Wang Y., Zhu M., Miller M., Fu Y.X. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol. Rev. 2009, 229:232-243.
46. Ward P.L., Koeppen H., Hurteau T., Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 1989, 170:217-232.
47. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 2005, 23:787-819.
48. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., Bluestone J.A., Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 1997, 186:229-238.
49. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012, 18:1386-1394.
50. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.-A., Reed K. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
51. Woo S.-R., Corrales L., Gajewski T.F. Innate immune recognition of cancer. Annu. Rev. Immunol. 2015, 33:445-474.
52. Yang X., Zhang X., Mortenson E.D., Radkevich-Brown O., Wang Y., Fu Y.-X. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol. Ther. 2013, 21:91-100.
53. Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., Fu Y.-X. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
54. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., Schietinger A., Philip M., Schreiber H., Fu Y.-X. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 2004, 5:141-149.
55. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., Fu Y.-X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 2005, 201:779-791.
56. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., Schreiber H., You Z., Kaynor C., Wang X. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 2007, 179:1960-1968.
57. Zhu M., Brown N.K., Fu Y.-X. Direct and indirect roles of the LTβR pathway in central tolerance induction. Trends Immunol. 2010, 31:325-331.
58. Zou W., Zheng H., He T.-C., Chang J., Fu Y.-X., Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res. 2012, 72:2980-2989.